NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a
class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by
visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of
Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead
plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Health Insurance Innovations, Inc. (NASDAQ: HIIQ)
Class Period: February 28, 2018 - November 27, 2018
Deadline: April 22, 2019
For more info: www.bgandg.com/hiiq
The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) a
substantial portion of Health Insurance Innovations’ revenue was derived from third parties; (2) these third parties used deceptive
tactics to sell Health Insurance Innovations’ policies, including overstating the policy’s coverage and/or selling under the
licenses of employees who had no involvement in the underlying sales; (3) regulatory scrutiny of these third parties would
materially impact Health Insurance Innovations’ operations; and (4) as a result of the foregoing, defendants’ positive statements
about Health Insurance Innovations’ business, operations, and prospects were materially misleading and/or lacked a reasonable
basis.
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)
Class Period: August 4, 2016 -
January 31, 2019
Deadline: April 26, 2019
For more info: www.bgandg.com/aveo
The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) the
TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from
the TIVO-1 trial presented in the June 2013; (2) tivozanib had insufficient survival data to meet FDA approval following its
initial 2013 rejection; (3) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and
(4) as a result, AVEO’s public statements were materially false and misleading at all relevant times.
CVS Health Corporation (NYSE: CVS)
Class Period: May 21, 2015 - February 20, 2019
Deadline: April 26, 2019
For more info: www.bgandg.com/cvs
The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) CVS
Health’s financial condition and expected earnings were deteriorating as a result of rising costs and poor results associated with
the Omnicare Acquisition; and (2) as a result, CVS Health’s public statements were materially false and misleading at all relevant
times.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
